Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2018-03-22
Target enrollment:
Participant gender:
Summary
RATIONALE: Pomalidomide and bortezomib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Bortezomib may also stop the growth of tumor cells by
blocking blood flow to the tumor. Drugs used in chemotherapy, such as dexamethasone, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving pomalidomide and bortezomib together with dexamethasone may kill
more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose
of bortezomib when given together with pomalidomide and dexamethasone and to see how well it
works in treating patients with relapsed or refractory multiple myeloma.